AXON Neuroscience, a clinical-stage biotech company and an industry leader in treating and preventing neurodegenerative diseases, is developing a promising vaccine candidate against COVID-19.

Based in Bratislava, Axon has over 20 years of experience in development of safe and immunogenic peptide vaccines. Its well-established scalable technology enabled the company to join quickly the global race to find the much needed remedy against COVID-19. Axon used its established peptide-based vaccine platform to produce a novel prophylactic COVID-19 vaccine, intended to treat infected patients and protect healthy individuals from infection.

Axon’s vaccine contains only selected epitopes that should prevent the virus from entering the cells and spreading throughout the body, without causing adverse side-effects. To support the most vulnerable populations, elderly individuals and those with immunodeficiencies, Axon has developed innovative proprietary technologies to stimulate their immune systems and increase their production of antibodies.

Find more information on the AXON Homepage and recent press release.